23:02 , Jan 18, 2019 |  BioCentury  |  Finance

Loxo's FOMO

Loxo Oncology Inc. (NASDAQ:LOXO) management held advanced licensing discussions with four potential partners during 2018 for its LOXO-292 program targeting RET, but the company instead chose an uncontested takeout offer from Eli Lilly and Co....
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
17:38 , Jan 11, 2019 |  BC Week In Review  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) said on Jan. 7 it reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in...
15:12 , Jan 7, 2019 |  BC Extra  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) has reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in the wake of the...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
18:25 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Sienna planning Phase III trials of pegcantratinib in psoriasis

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) plans to start Phase III trials in 2H19 of pegcantratinib (SNA-120) to treat psoriasis despite reporting that the compound missed the primary endpoint in a Phase IIb trial to treat pruritus...
18:24 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

FDA approves Loxo's larotrectinib, second tissue-agnostic approval from agency

FDA granted accelerated approval to Vitrakvi larotrectinib from Loxo Oncology Inc. (NASDAQ:LOXO), making the drug the second tissue-agnostic cancer treatment approved by FDA. Vitrakvi is a small molecule inhibitor of neurotrophic tyrosine kinase receptor 1...
00:13 , Nov 27, 2018 |  BC Extra  |  Company News

FDA approves Loxo's larotrectinib, second tissue-agnostic approval from agency

FDA granted accelerated approval to Vitrakvi larotrectinib from Loxo Oncology Inc. (NASDAQ:LOXO), making the drug the second tissue-agnostic cancer treatment approved by FDA. Vitrakvi is a small molecule inhibitor of neurotrophic tyrosine kinase receptor 1...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
22:27 , Nov 6, 2018 |  BioCentury  |  Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic. In a prospectus...